ESC Congress 2023 Amsterdam: Robert Mentz, HEART-FID trial, intravenous iron for heart failure with reduced ejection fraction
The HEART-FID trial built on research from the AFFIRM-AHF and IRONMAN trials to investigate the use of intravenous iron in treating heart failure with iron deficiency. In this touchCARDIO interview, we speak to Dr. Robert Mentz (Duke University, NC, US) regarding the HEART-FID trial, presented at the European Society of Cardiology Congress (ESC Congress) 2023 Amsterdam. We discuss the relationship between heart failure and iron deficiency, and the clinical findings regarding the effect of IV ferric carboxymaltose in patients with HFrEF and iron deficiency.
The presentation entitled ‘HEART-FID: Ferric Carboxymaltose in Heart Failure with Iron Deficiency’ was presented at the European Society of Cardiology Congress (ESC Congress) Amsterdam, 25–28, August 2023.
Questions:
- Could you provide us with a brief overview of the relationship between heart failure and iron deficiency? (0:18)
- What have previous studies in this area taught us, and how did they influence this research? (1:16)
- For this study, what were the primary and secondary endpoints and how well were they achieved? (3:34)
- In your opinion, what questions remain unanswered and what future studies should be done? (5:30)
Disclosures: Robert Mentz is a consultant for, and received grant/research support from: American regent, Vifor, Pharmacosmos
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Zoë Sidwell.
Filmed as a highlight of ESC Congress 2023.
Watch more content from ESC Congress 2023 in Amsterdam here.
If you’re interested in seeing more about heart failure, you may be interested in our similar video content:
John Boehmer, ACC 2023: MicrocorTM device for heart failure management, the BMAD trial
You may be interested in our similar journal content:
